Product Pipeline

PTG-100: A GI-restricted α4β7 integrin-specific antagonist for the treatment of moderate-to-severe UC

PTG-200: A potential first-in-class oral IL-23R antagonist for the treatment of moderate-to-severe IBD

PTG-300: An Injectable hepcidin mimetic being developed to treat iron overload disorders

Latest News

May 17, 2016

Protagonist Therapeutics to Present New Data for PTG-100 and PTG-200 at Digestive Disease Week 2016 read more

February 17, 2016

Protagonist Therapeutics Names Thomas P. O’Neil Chief Financial Officer read more

January 8, 2016

Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 read more

Upcoming Events

August 21-25, 2016

252nd American Chemical Society National Meeting & Exposition
Philadelphia, PA